The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Clinical aspects of inflammation in Alzheimer's disease
Abstract
In Alzheimer's disease (AD) there is increasing evidence that neurotoxicity is mediated by CNS inflammatory processes. These processes involve activation of microglia by amyloid-beta leading to release of pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha among others. Neurotoxic processes mediated by these cytokines may include direct neuronal death by enhancement of apoptosis, decreased synaptic function as evidence by inhibition of long-term potentiation, and inhibition of hippocampal neurogenesis. Central nervous system (CNS) inflammation may predate the development of senile plaques and neurofibrillary tangles in AD and may prove to be a more sensitive marker of prodromal AD. New developments in measuring CNS inflammation include measuring cytokine release by peripheral blood mononuclear cells and the development of PET markers of microglial activation. There is epidemiological evidence that circulating serum IL-6 is associated with poorer cognition. While epidemiological studies suggest a protective effect of NSAIDs against development of AD, controlled trials of NSAIDs to date have not shown any protective effect of drug. New anti-inflammatory agents for treating or preventing AD may include novel NSAIDs and opioid antagonists. These developments provide an alternative or potential adjunct to anti-amyloid therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“It is a leading cause of functional disability and institutionalization, with an estimated prevalence of 4.5 million people in the USA in 2000 increasing to 15 million in 2030 as the population ages (Hebert et al., 2003).”
BackgroundInfluentialLyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 1×
“Patients with AD frequently suffer from neuropsy- chiatric symptoms including depression, delusions, hallucinations and agitation (Lyketsos et al., 2000, 2002) which may be present at any stage of the disease.”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“The literature has been critically reviewed by McGeer et al. (1996) in a meta-analysis of 17 epidemiologic studies.”
MethodPatterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Cited by
Evidence for a cytokine model of cognitive function
McAfoose, J., & Baune, B. T. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.10.005 · Cited by 760
Morgan, J. T., Chana, G., Pardo, C. A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., & Everall, I. P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.024 · Cited by 749
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
“One of the most important processes involved in neuroinflammation is the beta-amyloid-induced activation of microglial cells [86], which in turn leads to the release of various inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha (TNF-a).”
BackgroundMushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331
Promising Health Benefits of the Strawberry: A Focus on Clinical Studies
Afrin, S., Gasparrini, M., Forbes-Hernandez, T. Y., Reboredo-Rodriguez, P., Mezzetti, B., Varela-López, A., Giampieri, F., & Battino, M. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b00857 · Cited by 307
Lee, J. K., Jin, H. K., Endo, S., Schuchman, E. H., Carter, J. E., & Bae, J.-S. (2010) · Stem Cells · doi:10.1002/stem.277 · Cited by 304
Fruit Polyphenols: A Review of Anti-inflammatory Effects in Humans
Joseph, S. V., Edirisinghe, I., & Burton-Freeman, B. M. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2013.767221 · Cited by 279
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Dhalaria, R., Verma, R., Kumar, D., Puri, S., Tapwal, A., Kumar, V., Nepovimova, E., & Kuca, K. (2020) · Antioxidants · doi:10.3390/antiox9111123 · Cited by 262
Janelsins, M. C., Mastrangelo, M. A., Park, K. M., Sudol, K. L., Narrow, W. C., Oddo, S., LaFerla, F. M., Callahan, L. M., Federoff, H. J., & Bowers, W. J. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080528 · Cited by 220
Diverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus
Moroz, N., Tong, M., Longato, L., Xu, H., & de la Monte, S. M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15103 · Cited by 151
Stress is critical for LPS-induced activation of microglia and damage in the rat hippocampus
Espinosa-Oliva, A. M., de Pablos, R. M., Villarán, R. F., Argüelles, S., Venero, J. L., Machado, A., & Cano, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.01.012 · Cited by 151
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
McIntyre, R. S., Kenna, H. A., Nguyen, H. T., Law, C. W. Y., Sultan, F., Woldeyohannes, H. O., Alsuwaidan, M. T., Soczynska, J. K., Adams, A. K., Cheng, J. S. H., et al. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0011-z · Cited by 83
Biomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87
Stigger, F. S., Zago Marcolino, M. A., Portela, K. M., & Plentz, R. D. M. (2019) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gly173 · Cited by 68
Fu, Y., Zhen, J., & Lu, Z. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3643 · Cited by 39
Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions
Berbée, J. F. P., Vanmierlo, T., Abildayeva, K., Blokland, A., Jansen, P. J., Lütjohann, D., Gautier, T., Sijbrands, E., Prickaerts, J., Hadfoune, M., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100576 · Cited by 25
Metadata
- Authors
- Rosenberg, P. B.
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 17
- Issue
- 6
- Pages
- 503-514
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W1995564836
- Cited by
- 158
- References
- 35
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.